StockNews.AI
BLCO
StockNews.AI
98 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch + Lomb Corporation - BLCO

1. Pomerantz LLP is investigating potential securities fraud by BLCO executives. 2. BLCO recalled intraocular lenses due to serious health concerns. 3. Stock price fell 9.83% following recall announcement. 4. First quarter 2025 results show a net loss of $54 million. 5. Growth outlook for 2025 revised down to 4.5%-6.5%.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The ongoing investigations and significant financial losses likely indicate further stock price declines. Historically for similar firms, fraud investigations have led to sustained declines until resolved.

How important is it?

The article discusses significant issues impacting BLCO's current stock status and future outlook. Investors and markets are likely to closely watch forthcoming legal developments and financial repercussions.

Why Short Term?

Immediate investor reactions and potential litigation outcomes could create volatility. Past occurrences show stocks typically react sharply in the wake of class action announcements.

Related Companies

AVDXVDTXHRC
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Bausch + Lomb Corporation (“Bausch + Lomb” or the “Company”) (NYSE: BLCO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Bausch + Lomb and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On March 27, 2025, Bausch + Lomb announced a voluntary recall of intraocular lenses on its enVista platform due to reports of toxic anterior segment syndrome, a potential complication in cataract surgery.  On this news, Bausch + Lomb’s stock price fell $1.54 per share, or 9.83%, over the following two trading sessions, to close at $14.13 per share on March 28, 2025.  Then, on April 30, 2025, Bausch + Lomb issued a press release reporting its financial results for the first quarter of 2025. Among other items, Bausch + Lomb reported an adjusted net loss of $54 million, compared to $24 million in adjusted net income for the same period in 2024. The Company also lowered its full-year growth outlook to a range of 4.5% to 6.5% year-over-year, compared to its previous guidance of 5.5% to 7.5%, citing the impact of the enVista product recall, among other factors.  On this news, Bausch + Lomb’s stock price fell $2.16 per share, or 15.74%, to close at $11.56 per share on April 30, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980

Related News